16 research outputs found
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer
Fungal systematics and evolution : FUSE 6
Fungal Systematics and Evolution (FUSE) is one of the journal series to address the âfusionâ between morphological data and
molecular phylogenetic data and to describe new fungal taxa and interesting observations. This paper is the 6th contribution in
the FUSE seriesâpresenting one new genus, twelve new species, twelve new country records, and three new combinations. The
new genus is: Pseudozeugandromyces (Laboulbeniomycetes, Laboulbeniales). The new species are: Albatrellopsis flettioides from
Pakistan, Aureoboletus garciae from Mexico, Entomophila canadense from Canada, E. frigidum from Sweden, E. porphyroleucum from Vietnam, Erythrophylloporus flammans from Vietnam, Marasmiellus boreoorientalis from Kamchatka Peninsula in the
Russian Far East, Marasmiellus longistipes from Pakistan, Pseudozeugandromyces tachypori on Tachyporus pusillus (Coleoptera, Staphylinidae) from Belgium, Robillarda sohagensis from Egypt, Trechispora hondurensis from Honduras, and Tricholoma
kenanii from Turkey. The new records are: Arthrorhynchus eucampsipodae on Eucampsipoda africanum (Diptera, Nycteribiidae)
from Rwanda and South Africa, and on Nycteribia vexata (Diptera, Nycteribiidae) from Bulgaria; A. nycteribiae on Eucampsipoda africanum from South Africa, on Penicillidia conspicua (Diptera, Nycteribiidae) from Bulgaria (the first undoubtful
country record), and on Penicillidia pachymela from Tanzania; Calvatia lilacina from Pakistan; Entoloma shangdongense from
Pakistan; Erysiphe quercicola on Ziziphus jujuba (Rosales, Rhamnaceae) and E. urticae on Urtica dioica (Rosales, Urticaceae)
from Pakistan; Fanniomyces ceratophorus on Fannia canicularis (Diptera, Faniidae) from the Netherlands; Marasmiellus biformis and M. subnuda from Pakistan; Morchella anatolica from Turkey; Ophiocordyceps ditmarii on Vespula vulgaris (Hymenoptera, Vespidae) from Austria; and Parvacoccum pini on Pinus cembra (Pinales, Pinaceae) from Austria. The new combinations
are: Appendiculina gregaria, A. scaptomyzae, and Marasmiellus rodhallii. Analysis of an LSU dataset of Arthrorhynchus including isolates of A. eucampsipodae from Eucampsipoda africanum and Nycteribia spp. hosts, revealed that this taxon is a complex
of multiple species segregated by host genus. Analysis of an SSUâLSU dataset of Laboulbeniomycetes sequences revealed support for the recognition of four monophyletic genera within Stigmatomyces sensu lato: Appendiculina, Fanniomyces, Gloeandromyces, and Stigmatomyces sensu stricto. Finally, phylogenetic analyses of Rhytismataceae based on ITSâLSU ribosomal DNA
resulted in a close relationship of Parvacoccum pini with Coccomyces strobi.http://www.sydowia.at/index.htmpm2021Medical Virolog
Recommended from our members
1935. COVID-19 mRNA Vaccination Reduces the Occurrence of Post-COVID Conditions in U.S. Children Aged 5-17 Years Following Omicron SARS-CoV-2 Infection, July 2021-September 2022
Abstract Background An estimated 1-3% of children with SARS-CoV-2 infection will develop Post-COVID Conditions (PCC). This study evaluates mRNA COVID-19 vaccine impact on likelihood of PCC in children. Methods A multi-site cohort of children enrolled 7/21/2021-9/1/2022 underwent weekly SARS-CoV-2 screening tests and were surveyed via self- or parental report 12/1/2022-5/31/2023 regarding PCC (defined as â„1 new or on-going symptoms lasting â„ 1 month after infection). Multivariable logistic regression was performed to estimate the occurrence of PCC by vaccination status among children aged 5â17 years whose first PCR-confirmed SARS-CoV-2 infection occurred in-study with Omicron variant, who completed the survey >60 days from infection, and who were vaccine age-eligible at time of infection per ACIP recommendations. Vaccination status was categorized as vaccinated (at least primary series completed >14 days before infection) and unvaccinated (no vaccine doses before infection). Vaccination status was verified through vaccine registry and/or medical records. Results Of 622 participants surveyed, 5% (n=28) had PCC (Table 1) and 67% (n=474) were vaccinated (Table 2). Surveys were completed a median (IQR) of 203.7 days (119.0â293.0) after infection. Children with non-Hispanic Black race/ethnicity and good/fair/poor self-rated baseline health were more likely to report PCC. Children aged 12-18 years, Non-Hispanic Asian and White children, those reporting symptomatic SARS-CoV-2 infection, and those with excellent/very good self-rated baseline health were more likely to report vaccination When comparing children with and without PCC symptoms, COVID-19 mRNA vaccination was associated with a decreased likelihood of >1 PCC symptom (aOR 0.66, 95% CI 0.43-0.99), >2 PCC symptoms (aOR 0.52, 95% 0.32-0.83), and respiratory PCC symptoms (aOR 0.53, 95% CI 0.33-0.87) (Table 3). Figure 1.Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid, Ages â„50 (N=564,303)Figure 2.Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid, Ages 18-49 (N=292,818)Figure 3.Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid, Ages 12-17 (N=17,178) Conclusion In this study, mRNA COVID-19 vaccination appeared to be protective against PCC in children following Omicron SARS-CoV-2 infection. The adjusted ORs correspond to an estimated 34%, 48%, and 47% reduced likelihood of >1, >2, and respiratory PCC symptoms among vaccinated children, respectively. These findings support COVID-19 vaccination for children and may encourage increased pediatric vaccine uptake. Disclosures Lisa Gwynn, MBA, MSPH, Merck: Honorari
Fungal Systematics and Evolution: FUSE 6
With only 138,000 formally described fungal species (Kirk 2019) out of an estimated 2.2â3.8 million (Hawksworth & LĂŒcking 2017) to 6 million (Taylor et al. 2014), between 97.7 and 93.7% of fungal species are left to be characterized. These may be discovered in poorly studied habitats and geographic areas (e.g., tropical rainforests), as molecular novelties, within cryptic taxa, in fungal collections (e.g., new species hidden under current names and in unidentified material), and during studies of plant and insect collections (Hawksworth & LĂŒcking 2017, Wijayawardene et al. 2020). This large discrepancy between described and undescribed species needs to be addressed and recent work has shown that mycologists are nowhere near levelling off the curve in describing new species (Hyde et al. 2020b). Together with other seriesâFungal Biodiversity Profiles (Rossi et al. 2020), Fungal Diversity Notes (Hyde et al. 2020a), Fungal Planet (Crous et al. 2020a), Mycosphere Notes (Pem et al. 2019), New and Interesting Fungi (Crous et al. 2020b)âthe Fungal Systematics and Evolution series published by Sydowia contributes to a much-needed acceleration of discovery and description of fungal diversity. The present paper is the sixth contribution in the FUSE series published by Sydowia, after Crous et al. (2015), HernĂĄndez-Restrepo et al. (2016), KrisaiGreilhuber et al. (2017), Liu et al. (2018), and Song et al. (2019). Altogether, one family, six genera, 67 species, and 22 combinations have been introduced in the FUSE series.publishedVersio
Fungal Systematics and Evolution: FUSE 6
With only 138,000 formally described fungal species (Kirk 2019) out of an estimated 2.2â3.8 million (Hawksworth & LĂŒcking 2017) to 6 million (Taylor et al. 2014), between 97.7 and 93.7% of fungal species are left to be characterized. These may be discovered in poorly studied habitats and geographic areas (e.g., tropical rainforests), as molecular novelties, within cryptic taxa, in fungal collections (e.g., new species hidden under current names and in unidentified material), and during studies of plant and insect collections (Hawksworth & LĂŒcking 2017, Wijayawardene et al. 2020). This large discrepancy between described and undescribed species needs to be addressed and recent work has shown that mycologists are nowhere near levelling off the curve in describing new species (Hyde et al. 2020b). Together with other seriesâFungal Biodiversity Profiles (Rossi et al. 2020), Fungal Diversity Notes (Hyde et al. 2020a), Fungal Planet (Crous et al. 2020a), Mycosphere Notes (Pem et al. 2019), New and Interesting Fungi (Crous et al. 2020b)âthe Fungal Systematics and Evolution series published by Sydowia contributes to a much-needed acceleration of discovery and description of fungal diversity. The present paper is the sixth contribution in the FUSE series published by Sydowia, after Crous et al. (2015), HernĂĄndez-Restrepo et al. (2016), KrisaiGreilhuber et al. (2017), Liu et al. (2018), and Song et al. (2019). Altogether, one family, six genera, 67 species, and 22 combinations have been introduced in the FUSE series